285 related articles for article (PubMed ID: 32206567)
1. Application of immunohistochemistry in diagnosis and management of malignant mesothelioma.
Chapel DB; Schulte JJ; Husain AN; Krausz T
Transl Lung Cancer Res; 2020 Feb; 9(Suppl 1):S3-S27. PubMed ID: 32206567
[TBL] [Abstract][Full Text] [Related]
2. [A comparative evaluation of immunohistochemical markers for the differential diagnosis between malignant mesothelioma, non-small cell carcinoma involving the pleura, and benign reactive mesothelial cell proliferation].
Szczepulska-Wójcik E; Langfort R; Roszkowski-Sliz K
Pneumonol Alergol Pol; 2007; 75(1):57-69. PubMed ID: 17541913
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic utility of D2-40, calretinin, CK5/6, desmin and MOC-31 in the differentiation of mesothelioma from adenocarcinoma in pleural effusion cytology.
Hyun TS; Barnes M; Tabatabai ZL
Acta Cytol; 2012; 56(5):527-32. PubMed ID: 23075894
[TBL] [Abstract][Full Text] [Related]
4. Can BAP1 expression loss in mesothelial cells be an indicator of malignancy?
Ozdemir HG; Kokten SC; Barisik NO
J Pathol Transl Med; 2020 Nov; 54(6):497-503. PubMed ID: 33153245
[TBL] [Abstract][Full Text] [Related]
5. The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions.
Illei PB; Ladanyi M; Rusch VW; Zakowski MF
Cancer; 2003 Feb; 99(1):51-6. PubMed ID: 12589646
[TBL] [Abstract][Full Text] [Related]
6. Combined use of novel epithelial (MOC-31) and mesothelial (HBME-1) immunohistochemical markers for optimal first line diagnostic distinction between mesothelioma and metastatic carcinoma in pleura.
González-Lois C; Ballestín C; Sotelo MT; López-Ríos F; García-Prats MD; Villena V
Histopathology; 2001 Jun; 38(6):528-34. PubMed ID: 11422496
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
[TBL] [Abstract][Full Text] [Related]
8. [Loss of BRCA associated protein 1 expression in malignant mesothelioma and its diagnostic application].
Guo ZY; Sun WY; Michele Y; Zhang JL; Hu D; Su HN; Yang WM; Mao W
Zhonghua Bing Li Xue Za Zhi; 2017 Oct; 46(10):699-703. PubMed ID: 29050072
[No Abstract] [Full Text] [Related]
9. Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.
Attanoos RL; Galateau-Salle F; Gibbs AR; Muller S; Ghandour F; Dojcinov SD
Histopathology; 2002 Jul; 41(1):42-9. PubMed ID: 12121236
[TBL] [Abstract][Full Text] [Related]
10. The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.
Saad RS; Lindner JL; Lin X; Liu YL; Silverman JF
Diagn Cytopathol; 2006 Dec; 34(12):801-6. PubMed ID: 17115439
[TBL] [Abstract][Full Text] [Related]
11. [BRCA1 associated protein 1 (BAP1) expression in pleural diffuse malignant mesothelioma: A comparative cytological and histological analyses on 50 patients].
Jaouen A; Thivolet-Bejui F; Chalabreysse L; Piaton E; Traverse-Glehen A; Isaac S; Decaussin-Petrucci M; Depaepe L; Fontaine J; Remy I; Maury JM; Brevet M
Ann Pathol; 2016 Apr; 36(2):111-9. PubMed ID: 26995100
[TBL] [Abstract][Full Text] [Related]
12. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
13. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids.
Politi E; Kandaraki C; Apostolopoulou C; Kyritsi T; Koutselini H
Diagn Cytopathol; 2005 Mar; 32(3):151-5. PubMed ID: 15690338
[TBL] [Abstract][Full Text] [Related]
14. EZH2, a unique marker of malignancy in effusion cytology.
Jiang H; Gupta R; Somma J
Diagn Cytopathol; 2014 Feb; 42(2):111-6. PubMed ID: 23636867
[TBL] [Abstract][Full Text] [Related]
15. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic Value of the EZH2 Immunomarker in Malignant Effusion Cytology.
Ang PP; Tan GC; Karim N; Wong YP
Acta Cytol; 2020; 64(3):248-255. PubMed ID: 31352449
[TBL] [Abstract][Full Text] [Related]
17. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
18. Malignant Mesothelioma Diagnosis.
Arif Q; Husain AN
Arch Pathol Lab Med; 2015 Aug; 139(8):978-80. PubMed ID: 26230591
[TBL] [Abstract][Full Text] [Related]
19. Cytological differential diagnosis among adenocarcinoma, epithelial mesothelioma, and reactive mesothelial cells in serous effusions by immunocytochemistry.
Su XY; Li GD; Liu WP; Xie B; Jiang YH
Diagn Cytopathol; 2011 Dec; 39(12):900-8. PubMed ID: 20836004
[TBL] [Abstract][Full Text] [Related]
20. Usefulness of p16/CDKN2A fluorescence in situ hybridization and BAP1 immunohistochemistry for the diagnosis of biphasic mesothelioma.
Wu D; Hiroshima K; Yusa T; Ozaki D; Koh E; Sekine Y; Matsumoto S; Nabeshima K; Sato A; Tsujimura T; Yamakawa H; Tada Y; Shimada H; Tagawa M
Ann Diagn Pathol; 2017 Feb; 26():31-37. PubMed ID: 28038708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]